Financial Advocates Investment Management’s Checkpoint Therapeutics CKPT Stock Holding History

Financial Advocates Investment Management’s Portfolio CKPT Stock Details CKPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,500	Closed	-$16K	–	774
2022 Q3	$16K	Hold	1,500	–	–	﹤0.01%	741
2022 Q2	$15K	Hold	1,500	–	–	﹤0.01%	677
2022 Q1	$27K	Hold	1,500	–	–	﹤0.01%	720
2021 Q4	$47K	Hold	1,500	–	–	﹤0.01%	757
2021 Q3	$50K	Hold	1,500	–	–	﹤0.01%	735
2021 Q2	$44K	Hold	1,500	–	–	﹤0.01%	727
2021 Q1	$47K	Hold	1,500	–	–	﹤0.01%	739
2020 Q4	$40K	Buy	+1,500	New	+$38K	﹤0.01%	710

Other funds holding CKPT

TwinBeech Capital Purchase, New York $965M AUM 0.23% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAM

PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

PAS

Park Avenue Securities New York $16B AUM 26.77% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Financial Advocates Investment Management's CKPT Position: Q4 2022 in Review

Financial Advocates Investment Management sold out of Checkpoint Therapeutics (CKPT) in Q4 2022, closing a stake of 1,500 shares — an estimated $16K sold.

Financial Advocates Investment Management first reported a position in CKPT in Q4 2020 and held it in 8 quarters. The position peaked at $50K in Q3 2021. 40 funds tracked by Wall St. Rank hold CKPT as of Q4 2022.

Financial Advocates Investment Management reported no remaining Checkpoint Therapeutics position as of Q4 2022 after selling out during the quarter.
Financial Advocates Investment Management sold 1,500 Checkpoint Therapeutics shares in Q4 2022, an estimated $16K.
Financial Advocates Investment Management first reported a position in Checkpoint Therapeutics in Q4 2020 and held it in 8 quarters.
Financial Advocates Investment Management's Checkpoint Therapeutics position peaked at $50K in Q3 2021.
40 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q4 2022.

Based on Financial Advocates Investment Management's 13F filing for Q4 2022, filed 15 Feb 2023.